Podcasts about astria

Josh Bowen is the founder of Astria, the easiest way to deploy decentralized rollups. Why you should listen In this conversation, Josh Bowen, co-founder of Astria, discusses the evolution and significance of decentralized sequencing in the blockchain ecosystem. He shares insights on the current state of rollups, the impact of regulatory changes, and the future of decentralized finance (DeFi). Josh also introduces Astria's new rollup, Flame, and emphasizes the importance of user experience in attracting wider adoption of DeFi. The discussion touches on the existential questions surrounding decentralization and the future of blockchain technology. Astria is building the shared sequencing layer for modular blockchains — an innovative approach designed to supercharge rollup scalability while preserving decentralization. By decoupling sequencing from execution, Astria gives developers the ability to launch fast, censorship-resistant rollups without needing to bootstrap their own validator sets or trusted sequencers. The core idea? Shared sequencing as a public good — one decentralized sequencer network serving many rollups. Under the hood, Astria's shared sequencer is powered by CometBFT and integrated with Celestia for data availability. This enables near-instant transaction inclusion and atomic cross-rollup composability, solving some of the most pressing coordination problems in the modular stack. Developers can spin up an Astria-integrated rollup with tools like Rollkit and benefit from out-of-the-box speed, fairness, and security. In a world of rollup proliferation, Astria is carving out the infrastructure to make modular chains truly interoperable and decentralized. Supporting links Stabull Finance Astria Andy on Twitter  Brave New Coin on Twitter Brave New Coin If you enjoyed the show please subscribe to the Crypto Conversation and give us a 5-star rating and a positive review in whatever podcast app you are using.

Josh Bowen is co-founder and CEO of Astria, a decentralized sequencing layer for Celestia rollups. He was previously a Software Engineer at Celestia and Google. 

Josh Bowen is co-founder and CEO of Astria, a decentralized sequencing layer for Celestia rollups. He was previously a Software Engineer at Celestia and Google. 

Hereditary angioedema (HAE) is a rare condition often due to reduced levels C1-inhibitor, which is a protein involved in various physiological processes in plasma, most notably with the complement system. C1-inhibitor also binds and inhibits plasma kallikrein and factor XIa, thereby affecting bradykinin production. It is believed that the disruptions of these processes cause fluid to leak from the blood to connective tissue, leading to HAE attacks. Owing to its rarity, HAE is often poorly recognized, leading to misdiagnoses and significant diagnostic delays. Being aware of the early signs and symptoms of this condition can lead to faster diagnosis and the use of effective therapies.This program is supported by independent medical education grants from Takeda. To earn CME credit please visit https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-hereditary-angioedema/lessons/consider-rare-suspecting-and-diagnosing-hereditary-angioedema-module/  Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in primary care, pediatrics, emergency care, otolaryngology, gastroenterology, and dermatology .Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:- Describe the early symptoms of HAE and its clinical relevance.- Apply best practices to diagnose HAE more efficiently to reduce diagnostic delays. Faculty Jonathan A Bernstein, MDProfessor of MedicineUniversity of Cincinnati Department of Internal MedicineDivision of Immunology, Allergy SectionPartner Advanced Allergy Services, LLCPartner Bernstein Clinical Research Center Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Bernstein discloses the following relevant financial relationships with ineligible companies:Advisory Board Consultant: Takeda/Shire, CSL Behring, KalVista, Pharming, Biocryst, Ionis, Intellia, Pharvaris, Astria and BiomarinGrant/Research Support: Takeda/Shire, CSL Behring, KalVista, Pharming, Biocryst, Ionis, Intellia, Pharvaris, Astria and BiomariSpeaker's Bureau: PharmingPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Jordan Oroshiba is CTO and Co-Founder of Astria (https://www.astria.org), a modular blockchain that allows individuals to deploy their own censorship-resistant rollup without relying on a centralized sequencer, easily allowing many rollups to share a single decentralized network of sequencers that's simple and permissionless to join. Jordan shares his thoughts on the modular blockchain ecosystem, issues Astria addresses across data availability and sequencing, and how Astria is re-inventing the space post mainnet. 

The gang has much deserved night of rest as they prepare for the final step of their journey: infiltrating the base of the Blood Moon Society.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

The gang makes a new friend, and uses their impeccable negotiation skills to broker an airtight deal.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

The gang takes their first blessed step off the mountain, and into a part of the woods that they find deeply disturbing: a beautiful field of flowers.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

In today's episode Josh Bowen, founder of Astria, and Jon Charbonneau join Mike to discuss the recent launch of Astria and its role in the Celestia ecosystem. The conversation explores how different blockchain architectures are converging toward similar designs. They examine the economics of L1 tokens, the challenges of achieving true decentralization, and debate the future of blockchain L1 differentiation. They close out by discussing how technical constraints and market forces will continue to shape the end game of crypto infrastructure. Resources: Josh Bowen @ DBA Research Day https://www.youtube.com/watch?v=5809YJpbhFg Jon Charb https://dba.mirror.xyz/UTPfxWe65dYrUu_RJX-5VkAJypFRyw3AZh6m0dRXYZk - - Follow Jon: https://x.com/jon_charb Follow Josh: https://x.com/Jskybowen Follow Mike: https://x.com/MikeIppolito_ Follow Expansion: https://x.com/ExpansionPod_ Subscribe on YouTube: https://www.youtube.com/@expansionpod Subscribe on Apple: http://apple.co/4bGKYYM Subscribe on Spotify: http://spoti.fi/3Vaubq1 Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ -- Timestamps: (00:00) Introduction (02:36) Extending Minimal Designs (09:42) Astria's Design (14:38) Purpose Built Infrastructure (24:09) POA Designs (36:22) Aggregation Summit Ad (37:05) What Makes L1 Tokens Valuable? (52:47) ZK's Impact on Astria (57:55) L1 Differentiation - - Disclaimer Expansion was kickstarted by a grant from the Celestia Foundation. Nothing said on Expansion is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Rex, Jon, and our guests may hold positions in the companies, funds, or projects discussed.

In this episode of Expansion, Mike is joined by Nick White of Celestia to explore the fundamental challenges of blockchain scaling. They dive deep into Celestia's approach to abundant blockspace, recent protocol upgrades including Shwab and Ginger, and the engineering tradeoffs between modular and monolithic blockchain designs. The conversation covers everything from fee market dynamics across different chains to the recent launch of Astria's decentralized sequencing layer. Thanks for tuning in! - - Follow Nick: https://x.com/nickwh8te Follow Mike: https://x.com/MikeIppolito_ Follow Expansion: https://x.com/ExpansionPod_ Subscribe on YouTube: https://www.youtube.com/@expansionpod Subscribe on Apple: http://apple.co/4bGKYYM Subscribe on Spotify: http://spoti.fi/3Vaubq1 Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ -- Join us at Permissionless III Oct 9-11. Use code: EXPANSION10 for a 10% discount: https://blockworks.co/event/permissionless-iii -- Timestamps: (00:00) Introduction (06:03) The Lazy Blockchain (12:19) Celestia Roadmap (19:57) Incoming Celestia Upgrades (31:28) Optimizing for Blockspace Demand (49:59) Astria Launch - - Disclaimer Expansion was kickstarted by a grant from the Celestia Foundation. Nothing said on Expansion is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Rex, Jon, and our guests may hold positions in the companies, funds, or projects discussed.

The gang consider their options as they wake in the relative safety of the abandoned moon temple, and make some measured, educated decisions.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

Rocket Pool activates the Saturn 0 upgrade. Vyper outlines security enhancements in the last year. Astria goes live on mainnet alpha. And Infinex raises $67.7 million from its community crowdfund. Read more: https://ethdaily.io/582

The gang spends the night in a seemingly abandoned temple, and have a totally chill, not at all terrifying evening!    ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

The gang learns about the importance of a good night's sleep, and why you should always tell your teammates if you hear yetis in the night.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

A few weeks back, Andy put out a tweet saying "no one wants to be branded as a shared sequencer anymore" and it triggered quite a few people. The "loss of revenue" is the biggest, ongoing misconception of why shared sequencing isn't the best option for rollups. Today were tackling that notion head on with Noah Pravecek from NodeKit and their shift from shared sequencing to building a Superbuilder. Initially, NodeKit aimed to build a shared sequencer, similar to what other projects like Espresso and Astria have worked on. Shared sequencers can coordinate block building and bring composability across chains, but NodeKit quickly recognized the limitations. While these solutions offer atomic inclusion (ensuring transactions are seen by all rollups), they don't guarantee that the transactions will actually be executed according to the rollups' state transitions. That gap—between inclusion and execution—is what their new design in the Superbuilder addresses head on. However, isn't it a winner takes all market? Why did Noah decide to build in this market? Where is the blue ocean to create meaningful PMF in a crowded space? The market for shared sequencing is highly competitive, but Noah answered and defended the technical differences quite well. We also discussed the obstacles of raising as a college dropout and first time founder, as well as what it's like building a brand in the space. And, of course, we touched on Noah's views of chain abstraction and how Nodekit fits into the picture. If you've been paying attention to our content focused around interoperability, this one's for you. A big problem space to be solved and were confident in the teams shipping. Enjoy. Website: https://therollup.co/ Spotify: https://open.spotify.com/show/1P6ZeYd.. Podcast: https://therollup.co/category/podcast Follow us on X: https://www.x.com/therollupco Follow Rob on X: https://www.x.com/robbie_rollup Follow Andy on X: https://www.x.com/ayyyeandy Join our TG group: https://t.me/+8ARkR_YZixE5YjBh The Rollup Disclosures: https://therollup.co/the-rollup-discl

In this episode, we dive deep into L2 scaling architecture with Josh from Astria and Terry from Eclipse. They explore the intricacies of shared sequencing, data availability, and the evolving landscape of L1 and L2 solutions. They unpack the technical challenges of decentralization, the role of Celestia, and the innovative approaches both projects are taking to create more efficient and scalable systems. From MEV capture to bridging solutions, this episode is a must listen! - - Follow Terry: https://x.com/0xtaetaehoho Follow Josh: https://x.com/Jskybowen Follow Rex: https://x.com/LogarithmicRex Follow nosleepjon: https://x.com/nosleepjon Follow Expansion: https://x.com/ExpansionPod_ Subscribe on YouTube: https://www.youtube.com/@expansionpod Subscribe on Apple: http://apple.co/4bGKYYM Subscribe on Spotify: http://spoti.fi/3Vaubq1 Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ -- Join us at Permissionless III Oct 9-11. Use code: EXPANSION10 for a 10% discount: https://blockworks.co/event/permissionless-iii -- Timestamps: (00:00) Introduction (01:46) Astria & Eclipse Builds (12:54) What is Settlement? (19:32) Permissionless III Ad (21:04) Decentralization Sequencer Spectrum (35:53) Incentives for Shared Sequencing (53:31) Based Sequencing Paradigm (58:02) Builder Pitch (1:03:29) Is DA a Commodity - - Disclaimer Expansion was kickstarted by a grant from the Celestia Foundation. Nothing said on Expansion is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Rex, Jon, and our guests may hold positions in the companies, funds, or projects discussed.

The gang gets serious as they scale the mountain, realizing that their survival hinges on three "c's" - communication, collaboration and cooperation. Luckily they're AP's - absolute professionals!  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

We're back, baby! After some unfortunate set backs (covid, root canal, general summer busyness) here's a brand new episode fresh from the pipe. Marvel as the gang argues their way up a mountain, attempting and failing to fulfill the promise of 'leaving no trace'.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

This episode, recorded at the 21st Annual Spine Orthopedic and Pain Management-Driven ASC + the Future of Spine Conference, features Dr. Alan Greenwald, Orthopedic surgeon at Astria Health. Here, he discusses his career shift towards osteoporosis management and the importance of early diagnosis and treatment of bone fragility. Dr. Greenwald shares insights on innovations in orthopedic care and his new venture, a bone health clinic in Montana.Disclosure: This content is subject to change without notice and offered for informational use only. You are urged to consult with your individual business, financial, legal, tax and/or other advisors and/or medical providers with respect to any information presented. Synchrony and any of its affiliates, including CareCredit, (collectively, “Synchrony”) makes no representations or warranties regarding this content and accept no liability for any loss or harm arising from the use of the information provided. All statements and opinions in this podcast are the sole opinions of the guest. Your receipt of this material constitutes your acceptance of these terms and conditions.

This episode, recorded at the 21st Annual Spine Orthopedic and Pain Management-Driven ASC + the Future of Spine Conference, features Dr. Alan Greenwald, Orthopedic surgeon at Astria Health. Here, he discusses his career shift towards osteoporosis management and the importance of early diagnosis and treatment of bone fragility. Dr. Greenwald shares insights on innovations in orthopedic care and his new venture, a bone health clinic in Montana.Disclosure: This content is subject to change without notice and offered for informational use only. You are urged to consult with your individual business, financial, legal, tax and/or other advisors and/or medical providers with respect to any information presented. Synchrony and any of its affiliates, including CareCredit, (collectively, “Synchrony”) makes no representations or warranties regarding this content and accept no liability for any loss or harm arising from the use of the information provided. All statements and opinions in this podcast are the sole opinions of the guest. Your receipt of this material constitutes your acceptance of these terms and conditions.

The gang parts way with their new friends and come to a fork in the road where a big decision awaits them.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

The gang discovers the source of the scream in the night, and makes a valiant attempt at becoming heroes.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

The gang embarks on their wilderness journey, and discovers the sweet siren call of a stable community.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

The gang prepares for a life on the run, and learns some stuff about Horus that they'd like to forget.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Support the Show! https://www.patreon.com/sarahellisfox    Connect with Us!  https://discord.com/invite/pQme6WV 

The gang tries to brute force a minefield and has a brush with death as Matt the Dungeon Master finally decides they simply cannot talk their way out of every situation (RIP CERBERUS INK!).  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe 

The gang attempts to rustle up some supplies in anticipation of their impending pilgrimage, and encounters the buffet of dangers that the city has to offer.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

Josh, the co-founder of Astria, discusses the journey from data availability layers to building a shared sequencer network. He explains the concept of shared sequencing and its advantages, such as amortizing the cost of engineering and providing a competitive experience for rollup developers. He also addresses the trade-offs and constraints of using a shared sequencer, including the block time and potential lock-in. Josh highlights the target market for shared sequencers and the potential value accrual in a world where multiple rollups tap into the same shared sequencer. Astria is focused on building a shared sequencer for rollups, which allows for faster and more cost-effective transactions. The market is still evaluating the cost and security trade-offs of shared sequencers versus centralized providers. The architecture of a shared sequencer relies on a distributed network, but it remains to be seen if it can be cost-competitive in the market. There is also an ideological question of where to draw the line between a developer building an app-specific rollup on a centralized sequencer and writing to a base layer. The landscape of optimistic rollups versus ZK rollups is constantly evolving, with ZK technology progressing significantly. Base sequencing refers to rollups that are purely dependent on the block producers of the L1, while shared sequencing involves a separate sequencing layer. Astria's go-to-market strategy involves vertically integrating and building their own rollups on top of the shared sequencer to demonstrate its viability. ⁠Josh's Twitter - https://twitter.com/Jskybowen Chapters 00:00 Introduction and Background 17:14 Target Market for Shared Sequencers 25:11 Value Accrual in a World with Shared Sequencers 32:41 The Evolving Landscape of Optimistic Rollups and ZK Rollups 44:11 The Definition and Challenges of Base Sequencing 50:41 Astria's Go-to-Market Strategy: Vertically Integrating and Building Their Own Rollups Disclosures Disclosures: This podcast is strictly informational and educational and is not investment advice or a solicitation to buy or sell any tokens or securities or to make any financial decisions. Do not trade or invest in any project, tokens, or securities based upon this podcast episode. The host and members at Delphi Ventures may personally own tokens or art that are mentioned on the podcast. Our current show features paid sponsorships which may be featured at the start, middle, and/or the end of the episode. These sponsorships are for informational purposes only and are not a solicitation to use any product, service or token. --- Send in a voice message: https://podcasters.spotify.com/pod/show/the-delphi-podcast/message

The gang tries to make sense of their new reality and form a plan for an uncertain future.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

After our episode with Tarun Chitra about value accrual in the modular stack, as well as thinking about it deeper we've came to our own conclusions. Josh Bowen, ex-Celestia team, and now founder of Astria blew it all out of the water today. Completely shifted the way we are thinking about RaaS providers, shared sequencers, and how they are approaching the competitive market of sequencing. We first dove into the modular architecture of Astria and their relationship with Celestia, and then dove deep into how Josh thinks about early stage tech markets. The vision behind Astria extends beyond facilitation of rollup deployment. Josh aspires to lower barriers to innovation in launching blockchains, in order to create a diverse ecosystem of rollups that transcend the limitations of existing setups. But, is this really possible? Can Astria do what other RaaS providers are doing at a tenth of the cost? Can they actually commoditize RaaS providers? Josh is a straight shooter and did not hold back when he pressed him about his mental models. We left quite impressed.

The gang celebrates some newfound treasure, and discovers an old friend is in town.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

The gang gets their priorities straightened out and heads out on a heist mission.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

This 25-minute CME-accredited program, hosted by Aleena Banerji, MD, Associate Professor at Harvard Medical School and Clinical Director of the Massachusetts General Hospital ( MGH) Allergy and Immunology Unit, highlights the current treatment options for patients with hereditary angioedema (HAE). Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from Ionis Pharmaceuticals Inc. Estimated time to complete: 0.50 hours Start date: January 31, 2024 End date: January 30, 2025To obtain CME credit, go to https://checkrare.com/learning/p-hereditary-angioedema-current-treatment-options/Activity Faculty Aleena Banerji, MD Associate Professor Clinical Director, MGH Allergy and Immunology Unit Harvard Medical School Massachusetts General Hospital Boston, MA Target Audience This activity has been designed to meet the educational needs of physicians specializing in allergy medicine, immunology, internal medicine, and pediatrics who may be involved in the care for individuals with HAE. Other healthcare providers (HCPs) may also participate. Learning Objectives After participating in the activity, learners should be better able to • Review current guidelines and unmet needs of patients with HAE Accreditation and Credit Designation In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians American Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPs Other members of the care team will receive a certificate of participation. Disclosure Statement According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows: Faculty Educator Dr. Banerji discloses the following relevant financial relationships with ineligible companies: • Research Grant: Takeda, Ionis Pharmaceuticals, Astria • Advisory Board: Takeda, BioCryst, Astria, Intellia, CSL Behring, KalVista, ADARx Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Method of Participation There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments at https://checkrare.com/learning/p-hereditary-angioedema-current-treatment-options/ Your certificate will be emailed to you in within 30 days. Privacy For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ Contact For any questions, please contact: CEServices@academycme.org Copyright © 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 16-minute CME-accredited program, hosted by Aleena Banerji, MD, Associate Professor at Harvard Medical School and Clinical Director of the Massachusetts General Hospital ( MGH) Allergy and Immunology Unit, highlights the future treatment options for patients with hereditary angioedema (HAE) presented at ACAAI 2023. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from Ionis Pharmaceuticals Inc. Estimated time to complete: 0.25 hours Start date: January 31, 2024 End date: January 30, 2025To obtain CME credit, go to https://checkrare.com/learning/p-hae-treatment-advances-highlights-from-acaai/Activity Faculty Aleena Banerji, MD Associate Professor Clinical Director, MGH Allergy and Immunology Unit Harvard Medical School Massachusetts General Hospital Boston, MA Target Audience This activity has been designed to meet the educational needs of physicians specializing in allergy medicine, immunology, internal medicine, and pediatrics who may be involved in the care for individuals with HAE. Other healthcare providers (HCPs) may also participate. Learning Objectives After participating in the activity, learners should be better able to • Understand clinical data of treatments in development for HAE Accreditation and Credit Designation In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPs Other members of the care team will receive a certificate of participation. Disclosure Statement According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows: Faculty Educator Dr. Banerji discloses the following relevant financial relationships with ineligible companies: • Research Grant: Takeda, Ionis Pharmaceuticals, Astria • Advisory Board: Takeda, BioCryst, Astria, Intellia, CSL Behring, KalVista, ADARx Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Method of Participation There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments at https://checkrare.com/learning/p-hae-treatment-advances-highlights-from-acaai/ Your certificate will be emailed to you in within 30 days. Privacy For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ Contact For any questions, please contact: CEServices@academycme.org Copyright © 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

On this episode of Rehash, we're speaking with Eshita, Head of Strategy at Astria, about the current state of crypto infra, why developer tooling is lagging, and we get to the bottom of what shared sequencers are.After spending a couple of years researching the crypto ecosystem, Eshita started to feel like a bystander and wanted to become more of an active participant in the ecosystem, so she recently joined Astria to help build out their shared sequencer network.Astria allows many rollups to share a single decentralized network of sequencers, which increases censorship resistance and enables faster block confirmations, all while allowing each rollup to maintain their own sovereignty. We then zoom out a bit and look at crypto infrastructure as a whole, and Eshita shares what she believes to be some of the most important pieces in the infra space right now as well as areas where she hopes to see more development and innovation moving forward. COLLECT THIS EPISODEhttps://www.rehashweb3.xyz/ FOLLOW USRehash: https://twitter.com/rehashweb3Diana: https://twitter.com/ddwchenEshita: https://twitter.com/eshitaAstria: https://twitter.com/astriaorg LINKSThe Myth of the Infrastructure Phase (USV): https://www.usv.com/writing/2018/10/the-myth-of-the-infrastructure-phase/  TIMESTAMPS0:00 Intro3:03 How Eshita got into crypto6:33 From researcher to operator7:30 What are shared sequencers?19:46 Current state of crypto infra28:28 What are modular blockchains, and what is Celestia?35:20 Will infra still be the focus of the next cycle?39:06 Eshita's bullish predictions for ETH/BTC ATH40:41 Follow Eshita DISCLAIMER: The information in this video is the opinion of the speaker(s) only and is for informational purposes only. You should not construe it as investment advice, tax advice, or legal advice, and it does not represent any entity's opinion but those of the speaker(s). For investment or legal advice, please seek a duly licensed professional.

The gang boards an airship and attempts to reassess their professional goals.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

This 40-minute CME-accredited program, hosted by Aleena Banerji, MD, Associate Professor at Harvard Medical School and Clinical Director of the Massachusetts General Hospital ( MGH) Allergy and Immunology Unit, highlights the current and future treatment options for patients with hereditary angioedema (HAE). Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from Ionis Pharmaceuticals Inc. Estimated time to complete: 0.75 hours Start date: January 31, 2024 End date: January 30, 2025To obtain CME credit, go to https://checkrare.com/learning/p-hereditary-angioedema-current-and-future-treatment-options/ Activity Faculty Aleena Banerji, MD Associate Professor Clinical Director, MGH Allergy and Immunology Unit Harvard Medical School Massachusetts General Hospital Boston, MA Target Audience This activity has been designed to meet the educational needs of physicians specializing in allergy medicine, immunology, internal medicine, and pediatrics who may be involved in the care for individuals with HAE. Other healthcare providers (HCPs) may also participate. Learning Objectives After participating in the activity, learners should be better able to • Review current guidelines and unmet needs of patients with HAE • Understand clinical data of treatments in development for HAE Accreditation and Credit Designation In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians American Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPs Other members of the care team will receive a certificate of participation. Disclosure Statement According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows: Faculty Educator Dr. Banerji discloses the following relevant financial relationships with ineligible companies: • Research Grant: Takeda, Ionis Pharmaceuticals, Astria • Advisory Board: Takeda, BioCryst, Astria, Intellia, CSL Behring, KalVista, ADARx Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Method of Participation There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments at https://checkrare.com/learning/p-hereditary-angioedema-current-and-future-treatment-options/ Your certificate will be emailed to you in within 30 days. Privacy For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ Contact For any questions, please contact: CEServices@academycme.org Copyright © 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

The gang consults some oracles and gets some hot tips about the consequences of their  actions.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

The gang spends some time in the Elemental Plane of Air, which works out great because all of them can definitely fly.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

The gang celebrates the glorious miracle of horses, and they also go to another dimension or something.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

Lordy lordy look who's 40! In this episode the gang does the unthinkable - and by unthinkable I mean bouncing a house party and looking GREAT while doing it.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

The gang takes a welcome moment of rest as they prepare for Mr. Feelys's extremely exclusive and VERY cool industry party (help, he's making me write this I ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

The gang attempts to solve extremely basic problems, and discovers the dark truth behind the man (?!) in the sarcophagus.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

The gang attempts to make the most of a second chance.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

The gang grapples with the aftermath of a major magic moment, and try to endure in the midst of Beetle's terrible, horrible, no good, very bad day. Horace meets an old buddy!  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox  

The gang meets a new foe, and are forced to make some very hard decisions.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show!

Hot on the heels of their arch nemesis Bindle, the gang deals with the plight of a flightless Beetle and meet some new friends.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show!

The gang discusses the logistics of flight as they delve deep into a cave system to find the greasiest little member of the Thieves Guild. ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show!

The gang wake up to find they have lost their buddy Bindle during a memory-erasing night, and must retrace their steps from the night before in order to find him. ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox

The gang navigates the trials and tribulations of the grocery store.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox

The gang meets with an old friend of Horace, and then spends a little time with Bindle, the city's greasiest bird.  ---  Credits:  Sarah Fox: Beetle Baby Markus Ristich: Horus Albright  Stacey Sellars: Naerra Corstay  Matt Klassen:  The Dungeon Mattster  ---  Connect with Us!  https://linktr.ee/adventurexe  ---  Support the show! https://www.patreon.com/sarahellisfox